NDR Presentation Hermes Pardini

Prévia do material em texto

Non Deal Roadshow Presentation
May 15-16th, 2017 | London
2
Agenda
CompanyOverview CompetitiveAdvantages OperatingHighlights Financial Highlights
3
Lab-to-Lab59% PSC41%
Company Overview
Business Segments Geographic Footprint
Gross Revenue by Business (2016)
1 In March 20172 Includes 9 stores from Guanabara, company acquired in Rio de Janeiro
Business segments Highlights
Lab-to-Lab: performs clinical analysis and imaging tests for other laboratories and hospitals, serving over 5,400 clients nationwide
PSC: 112 stores (patient service centers) in Minas Gerais, Goiás, São Paulo, and Rio de Janeiro, offering clinical analysis, imaging tests, vaccines, check-ups and others
+1,800 cities covered
Central Lab – Vespasiano (NTO)
112 PSC (1) 31
7
Progenetica and Diagnóstika
Regional Labs (NTAs)
Lab-to-Lab Presence
9
64#
Total volume of tests (2016)
5,400 clients
Clinical analysis64%Image36%
PSC: Regional leadership PSC: Gross revenue per type of test (2016)
70% Market Share in the metropolitanregion of Belo Horizonte (MG)
51% Market Share in the metropolitanregion of Goiânia (GO)
Lab-to-Lab: 55.2 million (+32.4% YoY)
PSC: 19.8 million (+4.8% YoY)
4
Brands
PSC brandsLab-to-Lab Brands
• Reference in Lab-to-Lab segment with 20 years of experience
• National presence with over 5,400 clients
• Reference in anatomic pathology 
• Highly specialized medical team, 32 years in the market with expertise in 19 segments of anatomic pathology
• Located in São Paulo and Rio de Janeiro
• Reference in oncogenetics with a 17-year track record 
• Specialized test portfolio as key rationale for the acquisition by Hermes Pardini
• Among 1st labs to implement high complexity molecular testing
• Located in Rio de Janeiro
Strategy: Product portfolio diversification through complementary specialized tests and market share expansion Strategy: Build national presence organically and through M&A
• Largest laboratory in Minas Gerais
• Reference in Minas Gerais state with a well recognized brand and a diversified portfolio of tests including clinical analysis and imaging, as well as vaccines. Has 57 years of experience
• Largest lab in Goiás with 31 years of experience and a top-of-mind brand. Portfolio includes clinical analysis, imaging and vaccines
• Acquired by Hermes Pardini in 2013 due to its relevance in the greater Goiânia area with 31 centers
• Acquired in December 2016: Opportunity to increase market share in Rio de Janeiro with 9 centers in the metropolitan area (Mar/17)
• Reference in multi-specialty imaging tests with 46 years of experience and pioneer in radioactive diagnostics and treatment
5
Hermes Pardini Track Record
Hermes Pardini Track Record
1959-2001: Foundation and Creation of New Segments 2007-2011: Professionalization As of 2011: Accelerated Growth Strategy
Beginning of diagnostics operations
Launch of imaging and anatomic pathology services
Launch of Lab-to-Lab services
Creation of the human genetics department
Launch of vaccine services
Professionalization of management and 10-yr strategic plan definition
Implementation of Corporate Governance
Business segmentation into Lab-to-Lab and PSC
Lab-to-Lab: Specialization and market share expansion, organically and through M&A
PSC: Build national presence organically and through M&A
Inauguration of NTO to support Lab-to-Lab expansion
Entry of GáveaInvestimentos to support M&A strategy and further professionalization 
Lab-to-Lab M&A Strategy:
PSC M&A Strategy:
Lab-to-LabM&A Strategy:
PSC M&A Strategy:
M&A strategy:
Acquisition of CMNG
Launch of Hermes Pardini brand in SPSão Paulo Goiás
Rio de Janeiro
2007 2010 2011 2012 2013 2016 20171959 1994 1997 1998 2001
IPO
Project Enterprise 2018
2018
6
Management Team
Executives Position Years at Hermes Pardini Previous Experience and Education
Camilo de Lelis CFO / IR 7
• Prior to joining Hermes Pardini, Mr. de Lelis worked in the mine and automotive industries with London & Scandinavian Metallurgical and Fiat (Brazil , Mexico and USA) • Bachelor in Accounting Sciences from Universidade Newton Paiva. Graduate degree from UNA and MBA from Harvard-UDEM
Dr. Roberto Santoro CEO 14
• Prior to becoming CEO, Dr. Santoro was Hermes Pardini’s Medical Diagnostics Director • Undergraduate and graduate medical degree from UFMG. Executive MBA at Fundação Dom Cabral and post-MBA at Kellogg
Alessandro Ferreira CommercialOfficer 19
• Prior to joining Hermes Pardini, Mr. Ferreira was a biotechnology and biochemical professor at the post-graduate level• Bachelor in Biochemical Pharmacy at UFMG. Master and doctorate degree from UFMG and MBA degree from IBMEC
Dr. Guilherme Collares OperationsOfficer 7
• Technical Director for 5 years at Lab Rede. Previous Emergency coordinator at UFMG Hospital das Clínicas and president of the Clinical Pathology Dep. (MG)• Medicine undergraduate and master degrees from UFMG. Executive MBA from FGV
Adriana Linhares BusinessOfficer 18
• Prior to becoming Business Director, Adriana Linhares was Hermes Pardini’s PSC Corporate Manager• Bachelor in Biochemical Pharmacy from UFMG. Graduate degree in Clinical Analysis from UFMG and executive MBA degree from IBMEC
7
Consistent Gross Revenue Growth
Note: ¹ includes eliminations. Does not include Guanabara
Gross Revenue and Gross Margin - Consolidated¹
Lab-to-Lab: Gross Revenue and Gross Margin PSC: Gross Revenue and Gross Margin
Acquisitions
Gross Margin
Gross Margin
# of tests (MM)
Average ticket (R$)
R$mm
# of tests (MM)
Average ticket (R$)
Gross Margin
# of tests (MM)
Average ticket (R$)
619 745 826 971 
2013 2014 2015 2016
34.4% 34.3% 34.3%
13.59 13.33
48.5 54.8 72.8
12.76 13.94
59.2
32.7%
348 427 473 
579 
2013 2014 2015 2016
35.9% 37.5%
32.4
10.74
38.0
11.23
41.7
11.35
55.2
10.50
38.7% 37.5%
278 330 369 405 
2013 2014 2015 2016
33.3% 30.5%
15.9
17.42
17.6
18.77
18.9
19.54
19.8
20.43
28.5% 25.4%
8
Evolution of Profitability Levels
Adjusted EBITDA and margin
R$mm
Net income and margin
Note: does not include Guanabara
136 
177 186 
200 
2013 2014 2015 2016
25.3%23.6% 24.1% 22.2%
61 
84 84 
103 
2013 2014 2015 2016
12.1%10.6% 10.9% 11.5%
9
Low Leverage with Superior Returns
Net Debt and Net Debt / EBITDA – annual evolution
R$mm
ROIC (without goodwill) 
ROIC (with goodwill) Net Debt and Net Debt / EBITDA – 4Q16 x 3Q16
Note: does not include Guanabara
8.9
(45.6) (47.1)
28.7
2013 2014 2015 2016
7.2% -26.5% -26.6% 15.4%
27%
36% 35% 33%
2013 2014 2015 2016
21% 25% 25% 21%
2013 2014 2015 2016(89.7)
28.7
3T16 4T16
-47.4% 15.4%
10
Agenda
CompanyOverview CompetitiveAdvantages OperatingHighlights Financial Highlights
11
Organic growth opportunities
Centralized production with efficient logistics
PSC: High Reliability and Operational Excellence
Focus on R&D: High Specialization and Development of New Tests
Experience in M&A activities
Lab-to-Lab: Unique Value Proposition
Competitive advantages
2
3
4
5
1
6
Key
 Dif
fere
ntia
ting
 Att
ribu
tes
Key
 Dif
fere
ntia
ting
 Att
ribu
tes
Gro
wth
 Av
enu
es
Gro
wth
 Av
enu
es
12
Centralized production with efficient logistics1
Centralized production... …supported by regional sites (NTA) and an efficient logistics network:
Central Lab: NTO Vespasiano
3 supporting regional sites (NTAs)
Central Laboratory (NTO)
2 supporting specializedsites (NTAs)
5,400+ Lab-to-Lab Clients
112 Pardini PSCs
Central Lab NTO
São Paulo
Onco-genetics
Goiânia
RH RH
RH
RH
RH
RH
Belo Hori-zonte
Path.Anat.
13
Lab-to-Lab: Unique Value Proposition2
Competitive Cost Structure Competitive Cost Structure 
R&D and Broad Test MenuR&D and Broad Test Menu
Reliability of ResultsReliability of Results
Lab-to-Lab
Medical SupportMedical Support
Fast Turnaround TimeFast Turnaround Time
IT IntegrationIT Integration
14
PSC: High Reliability and Operational Excellence3
Medical excellence, broad portfolio and expertise with customer care increases the value perceived by patients and physicians, while operating excellence allows Hermes Pardini to offer competitive prices for HMOs
+ Operating ExcellenceHigh Value Perceived by Patients and Physicians 
Real time monitoring of KPIs
Competitive Cost Structure
Expertise in Cross-Selling
Real-Time Operations Monitoring
1
2
3
Excellence in Patient Care
Brand Recall and Reliability of Results
One-Stop-Shop
1
2
3
One-Stop-Shop Real-Time MonitoringOne-Stop-Shop Real-Time Monitoring
Clinical Analysis
Imaging Tests
Vaccines
Nutrition
Check-ups
OTC Wellness Products
Precision Medicine
15
Focus on R&D: High Specialization and Development of New Tests4
(1) Source: Folha de São Paulo
Hermes Pardini’s R&D excellence allows for a leading positioning in development of exclusive tests
New Test DevelopmentNew Test Development Research Production and Quality RecognitionResearch Production and Quality Recognition
• Zika Virus case study: 1st lab in Brazil to develop in-house methodology for viral detection
• Zika virus test was only offered by laboratories outside Brazil with an avg. cost of R$1,000 and 50 days of turnaround time
• Hermes Pardini developed this test in-house and was able to reduce patient cost by 50% and the turnaround time to only 1 week
1st Place in Personalized Medical Research
3 nominations 2 oral presentations
Quality Certificates
American Association of Clinical Chemistry
16
++
Expansion Strategy:
• Strengthen presence in southeast region and expand to key metropolitan cities in the south and northeast
• Increase bargaining power with payers
• Continue to focus on higher return clinical analysis with imaging as a support
• Cross-selling leverage
New PSCs will be offered in a one-stop-shop format: units with ~1,500m², broad menu of clinical analysis and imaging tests, vaccines, check-ups and anatomic pathology
PSCs per Region
5 Organic Growth Opportunities
(1) December 2016, including the stores acquired through Guanabara laboratory, in Rio de Janeiro
Minas Gerais58%
Goiás28%
Rio de Janeiro9%
São Paulo5%
New Labs in Existing Routes
New Labs in Existing RoutesIncrease Share of Wallet in Client Labs
Increase Share of Wallet in Client Labs
Lab Portfolio Expansion and % Outsourced
Lab Portfolio Expansion and % Outsourced
New Labs in New RoutesNew Labs in New Routes
1
2
3
4
Lab-to-Lab Strategy
Long Term Growth Strategy:
Further develop relationships in Pharma
Increase volume of toxicology tests
Expand telemedicine
Focus on precision medicine
Short Term Growth Strategy:
Multiple avenues for organic value creation
PSC Strategy
17
Experience in M&A activities
6 Experience in M&A activities
December 2016
• Strengthen penetration in Rio de Janeiro• Complete portfolio of tests (mainly nuclear medicine and radiology)
July 2013
July 2013
December 2012
December 2012 October 2012
• Acquisition of clinical analysis market leader in Mid-West region
• Increase in specialized anatomic pathologic tests’ production capacity
• Renowned medical team
• Acquisition of national paternity test leader, strengthening biotechnology portfolio
• Opportunity to acquire local authority portfolio
• Entry in São Paulo diagnostics market, largest national market
• Focused on imaging tests. Opportunity to expand in clinical analysis and vaccines
• Opportunity to use its lab as a NTA for Lab-to-Lab clients in São Paulo 
• Acquisition of Pregenetica’s genetics and personalized medicine know-how
• Specialized on high complexity molecular tests
Revenue and Margin Expansion Business Diversification
18
Agenda
Company Overview Competitive Advantages Operating Highlights Financial Highlights
19
Operating Highlights 1Q17
• Completion of the IPO process in February, with the Company raising about R$187 million in the Primary Offer;• We have officially started Project Enterprise 2018, with the distribution RFI (Request for Information) to the largest technology suppliers for laboratory automation;• Construction of the advanced laboratory (Núcleo Técnico Avançado – NTA) in Rio de Janeiro, with opening expected for May, 2017. This laboratory will be an important pillar to our strategy of increasing clinical analysis services in Guanabara and to strengthen our competitive position in the Lab-to-Lab business in Rio de Janeiro.
BM&FBovespa event – February, 2017 Central Laboratory (NTO) – Vespasiano MG Construction of the advanced laboratory (NTA) in Rio de Janeiro
20
Opening of the new store in São Gonçalo (RJ)
Highlights of the new unit in São Gonçalo (Rio de Janeiro), opened in January 2017:• Service area of 800 m²;• Capable of offering clinical analysis and imaging tests;• Swift accreditation by major healthcare operators in the region;• Ramp-up of revenues since opening was above expectation.
21
1Q17 Highlights: Lab-to-Lab segment
• Consistent growth in volume of tests (+26.3%) and revenue per client (+12.8%);• Commercial strategy focused on the increase of the client base: over 4,800 clients generated revenues during the 1Q17 (+5.5% YoY);• Expertise on client relationship and high quality of services has resulted in the improvement of Same Lab Sales indicator (+14.7%).
22
1Q17 Highlights: PSC segment
• Acquisition of Guanabara, in Rio de Janeiro, focused on imaging tests, has contributed to the increase in number of tests (+7.4%) and in gross revenue per m2 (+30.1%);• Resilience in a market of high concentration of lives among a few healthcare operators: increase in same store sales (SSS) basis of 7.5%;• NPS (Net Promoter Score) for Hermes Pardini reached 73% during 1Q17;• Expansion in Rio de Janeiro, with the opening of one new store in São Gonçalo .
23
Agenda
CompanyOverview CompetitiveAdvantages OperatingHighlights Financial Highlights
24
Consolidated Gross Revenues
• Strong increase in gross revenue in both business units;• Eliminations shown in the above table are mainly intercompany transactions which are excluded for calculating gross book revenues.
Evolution of gross revenue per business unit
R$ MM 1Q16 1Q17 Variation
Lab-to-Lab 128.2 152.5 19.0%
PSC 101.3 140.5 38.6%
Eliminations -2.2 -4.0 81.4%
Consolidated 227.3 289.1 27.2%1Q16 1Q17Lab-to-Lab PSC
227.3
289.1
+ 27.2%
55.8%
44.2% 48.0%
52.0%
Gross Revenue (R$ MM)
25
Gross Revenues of the Lab-to-Lab segment
• The significant increase in Gross Revenue (+19.0%) was due mainly to higher number of tests (+26.3%) and number of clients which generated revenue in the period (+5.5%);• Gross revenue per client showed year-on-year growth of 12.8%, reflecting the strategy of improving the relationship with existing clients and increasing the share of wallet;• Expertise on client relationship and high quality of services has resulted in the improvement of Same Lab Sales indicator, which grew by 14.7%.
26
Gross Revenues of the PSC segment
• Acquisition of Guanabara, in Rio de Janeiro, focused on imaging tests, has contributed to the increase in numberof tests (+7.4%) and in gross revenues from the PSC segment (+38.6%);• Imaging tests represented circa 50% of gross revenues from the PSC segment;• Gross revenues, in terms of same store sales, grew by 7.5%.
+ 7.4%
27
Deductions from Gross Revenues and Net Revenues
• Total deductions remained constant at 7.5% of gross revenues in both quarters;• The purchase of Guanabara increased the share of the PSC segment to 47.8% of our consolidated net revenue in 1Q17.
Deductions from Gross Revenues
R$ MM 1Q16 1Q17 Variation
Disallowances -2.6 -3.3 27.8%
Cancelled Sales and Other Rebates -0.5 -1.1 110.2%
Taxes on Services -13.8 -17.2 24.2%
Cancellations and Deductions -17.0 -21.6 27.4%
1Q16 1Q17
Lab-to-Lab PSC
Net Revenue per Business Line (R$ MM)
44.1%
210.3
267.4
+ 27.1%
55.9%
47.8%
52.2%
28
Gross Profit and Gross Margin
• In the Lab-to-Lab segment, the rise in gross margin is related to the increase in volume of tests, efficiency gains from negotiations with suppliers and the maturity of certain clients which joined the active client base of IHP during 2016;• In the PSC segment, gross margin increased due mainly to the incorporation of results from Guanabara, higher number of tests and closure of certain service units during 2016. 
29
Operating Expenses (Selling, Administrative and Other)
• Operating expenses remained unchanged at 15.4% of net revenues in both 1Q17 and 1Q16.• The increase in general and administrative expenses was due mainly to:• Operation of Guanabara laboratory: +R$ 4.3 MM;• Personnel expenses: +R$ 4.1 MM;• Expenses related with the integration of Guanabara: +R$ 0.5 MM.
Variation of major Operating Expenses
R$ MM % Net Revenue R$ MM % Net Revenue
Selling Expenses 13,2 6,3% 15,4 5,8%
General and Administrative Expenses 13,8 6,6% 23,3 8,7%
Other Operating Income / Expenses 5,3 2,5% 2,6 1,0%
Total Operating Expenses 32,3 15,4% 41,2 15,4%
R$ MM 1Q16 1QT17
30
Financial result and Income tax / social contribution
• Income tax (IR) and social contribution (CSLL): the effective tax rate was 33.7% of earnings before taxes, which is close to our standard tax rate of 34.0%;• The Company intends to start amortizing the goodwill on company acquisitions (around R$ 240.4 million, as per IHP’s financial statements) in the second half of 2017.
Income Tax (IR) and Social Contribution (CSLL)Financial Result
R$ MM 1Q16 1Q17 Variation
Net Finance Result -8.9 -4.5 -49.6%
Finance Income 4.9 5.1 4.5%
Income from financial investments 5.0 4.2 -16.2%
Others -0.2 0.9 -629.9%
Finance Costs -15.0 -9.9 -34.2%
Interest on borrowings -2.3 -4.9 115.6%
Interest on installments -1.2 -1.0 -19.5%
Restatement of investment call option debt -5.6 -0.3 -95.2%
Other finance costs -6.0 -3.7 -37.2%
Foreign Exchange Variation 1.3 0.3 -74.8%
Foreign exchange income 1.9 0.5 -76.0%
Foreign exchange expenses -0.7 -0.1 -78.4%
R$ MM 1Q16 1Q17 Variation
Earnings Before Taxes (EBT) 30.3 47.2 55.7%
Expected taxes (standard rate of 34%) -10.3 -16.0 55.7%
Effect on the results of subsidiaries taxed under the presumed profit method 0.9 0.8 -3.2%
Other exclusions (additions), net -0.2 -0.7 300.6%
Income tax and social contribution -9.6 -15.9 65.4%
% EBT -31.7% -33.7% -197 bps
Current -12.2 -16.5 35.0%
Deferred 2.6 0.6 -76.6%
31
Net Income and EBITDA
• Persistent high profitability margins: adjusted EBITDA margin of 24.1% and net income margin of 11.7% thanks to improved operational margins in both segments;• Non-recurring items which affected EBITDA in 1Q17 includes write-off of improvements on units that were subsequently closed (R$ 0.5 million), write-off of tangible fixed assets (R$0.5 million) and specific expenses associated with the integration process of Guanabara (R$0.5 million).
EBITDA
R$ MM 1Q16 1Q17 Variation
Net Income 20.7 31.3 51.2%
Finance Result 8.9 4.5 -49.6%
Depreciation and amortization 8.8 10.4 18.5%
Income tax and social contribution 9.6 15.9 65.4%
(+) Non recurrent/operating items 3.6 2.4 -34.1%
Adjusted EBITDA 51.6 64.4 24.9%
margin 24.5% 24.1% -43 bps
(+) Non recurrent/operating items -3.6 -2.4 -34.1%
EBITDA 48.0 62.1 29.4%
margin 22.8% 23.2% +40 bps
32
Trade Receivables
• Days of sales outstanding was down to 73 days in 1Q17, due mainly to higher participation of the PSC segment in the Company’s revenue mix and changes in the payment policies of the sales area in the Lab-to-Lab segment;• Our receivables portfolio is at an extremely healthy level: • 88.5% of receivables are in order.• we have set up a provision for all receivables overdue for more than 120 days. 
R$ MM 1Q16 2Q16 3Q16 4Q16 1Q17
Trade Receivables 202.5 201.1 204.5 212.1 229.6Current 175.4 171.8 175.9 177.3 203.3
From 1 to 60 days past due 13.9 16.4 18.0 21.2 13.4
From 61 to 120 days past due 3.0 5.5 3.4 2.6 2.6
Over 120 days past due 8.0 3.9 5.4 7.4 8.9
Other current amounts 2.2 3.5 1.7 3.6 1.4
Provision for disallowances and doubtful accounts -13.5 -10.4 -7.2 -12.4 -11.5Total 189.0 190.8 197.3 199.7 218.1
Net Revenue 210.3 230.0 234.8 224.3 267.4
Days of Sales Outstanding 81 75 76 80 73
33
Debt
• In 1Q17, we once more showed a net cash position, mainly because of the completion of the IPO (primary offer);• Funding of a total of R$ 210 million, through a simple, non-convertible debenture issue(CVM476) with a total tenor of five years and CDI + 1.57% rate;• Healthy capital structure (net debt / EBITDA LTM of -0.3x).
Net debt and Covenants
R$ MM 1Q16 1Q17 Variation
Gross Debt (Borrowings) 115.2 302.4 162.4%
Cash and Cash Equivalents 147.8 363.1 145.7%
Net Debt -32.6 -60.7 86.4%
Net Debt / EBITDA LTM -0.2 -0.3 67.7%
EBITDA LTM / Financial Result LTM -9.2 21.6 -335.6%
34
Cash Flow and ROIC
• Net cash flow from operations amounted to R$8.8 million in 1Q17;• ROIC excluding goodwill was 30.8% in 1Q17, one of the highest in our sector.
Cash Flow Summary
R$ MM 1Q16 1Q17 Variation
Net Income 20.7 31.3 51.2%
Non-cash itens 33.5 37.3 11.2%
D Working Capital:
Receivables -69.2 -19.8 -71.3%
Trade Payables 6.9 -1.0 -114.5%
Payroll/Social Security and Installments -9.6 -13.2 36.7%
Other Assets and Liabilities 11.4 1.6 -86.1%
Income Tax and Social Contribution and others paid -17.6 -27.3 54.9%
Operational Cash Flow -24.0 8.8 -136.8%
Investing Activities -4.8 -10.8 126.0%
Financing Activities -12.2 240.7 2080.5%
Cash Flow -40.9 238.7 -683.4%
Conversion (Operational Cash / EBITDA) -50.0% 14.2% +6421 bps
35
Events after the reporting period: payment of dividends
• At the General Shareholders Meeting held on Abril 28, the shareholders approved distribution of dividends of R$ 1.21 per share, totaling R$ 158.5 million;• The shareholders which held shares on April 28, 2017 will be entitled to receive such dividends;• Dividend Yield of approximately 5.4%, based on the stock price of R$ 22.51 per share (closing price on April 28, 2017);• Payment to shareholders shall be made in May 2017.
Calculation Dividends
Number of Shares PARD3 130,978,595
(x) Dividends per Share R$ 1.21
(=) Total Dividends Payable R$ 158,484,099.95
36
Notice and IR Contacts
This presentation contains certain forward-looking statements concerning the business prospects, projections ofoperating and financial results and growth potential of the Company, which are based on management’s currentexpectations and estimates of the future performance of the Company. Although the Company believes suchforward-looking statements are based on reasonable assumptions, it can give no assurance that its expectationswill be achieved. Expectations and estimates that are based on the future prospects of the Company are highlydependent upon market behavior, Brazil’s political and economic situation, existing and future regulations of theindustry and international markets and, therefore, are subject to changes outside the Company’s andmanagement’s control. TheCompany undertakes no obligation to update any information contained herein or torevise any forward-looking statement as a result of new information, future events or other information.
This presentation contains certain forward-looking statements concerning the business prospects, projections ofoperating and financial results and growth potential of the Company, which are based on management’s currentexpectations and estimates of the future performance of the Company. Although the Company believes suchforward-looking statements are based on reasonable assumptions, it can give no assurance that its expectationswill be achieved. Expectations and estimates that are based on the future prospects of the Company are highlydependent upon market behavior, Brazil’s political and economic situation, existing and future regulations of theindustry and international markets and, therefore, are subject to changes outside the Company’s andmanagement’s control. The Company undertakes no obligation to update any information contained herein or torevise any forward-looking statement as a result of new information, future events or other information.
Aviso
e-mail: ri@grupopardini.com.br
site: www.grupopardini.com.br/ri
Phone: +55 (31) 3629-4503
e-mail: ri@grupopardini.com.br
site: www.grupopardini.com.br/ri
Phone: +55 (31) 3629-4503
Contact: Investor Relations